Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.695
-0.065 (-3.69%)
Oct 30, 2026, 12:57 PM EDT - Market open
Acrivon Therapeutics Employees
As of December 31, 2025, Acrivon Therapeutics had 76 total employees, including 74 full-time and 2 part-time employees. The number of employees decreased by 2 or 2.56% compared to the previous year. That makes Acrivon Therapeutics the 32,982nd largest employer in the world and 4,302nd in the United States.
Employees
76
Change (1Y)
-2
Growth (1Y)
-2.56%
Revenue / Employee
n/a
Profits / Employee
-$976,645
Market Cap
72.64M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 76 | -2 | -2.56% | 74 | 2 |
| Dec 31, 2024 | 78 | 17 | 27.87% | 75 | 3 |
| Dec 31, 2023 | 61 | 17 | 38.64% | 58 | 3 |
| Sep 30, 2023 | 59 | 17 | 40.48% | 56 | 3 |
| Jun 30, 2023 | 53 | 17 | 47.22% | 50 | 3 |
| Mar 31, 2023 | 48 | 12 | 33.33% | 45 | 3 |
| Dec 31, 2022 | 44 | - | - | 41 | 3 |
| Sep 30, 2022 | 42 | - | - | 39 | 3 |
| Jun 30, 2022 | 36 | - | - | 35 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Inovio Pharmaceuticals | 112 |
| Neumora Therapeutics | 63 |
| Corbus Pharmaceuticals Holdings | 36 |
| Cardiff Oncology | 31 |
| Cingulate | 14 |
| Cognition Therapeutics | 14 |
| MAIA Biotechnology | 13 |
| Nutriband | 13 |
ACRV News
- 1 day ago - Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium - GlobeNewsWire
- 10 days ago - Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 - GlobeNewsWire
- 7 weeks ago - Acrivon Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 7 weeks ago - Acrivon Therapeutics Slides: Corporate presentation - Filings
- 1 month ago - Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics reports Q2 EPS (43c), consensus (50c) - TheFly
- 2 months ago - Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts - GlobeNewsWire